Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 1.00 |
| ▸ | CA2 | P00918 | 5/20 | 1.00 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | PDE4A | P27815 | 1/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 4/20 | 0.51 |
| ▸ | MAOB | P27338 | 4/20 | 0.51 |
| ▸ | HTR6 | P50406 | 2/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1894093 | 0.90 | CA1 (0.82) | CA1CA2ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL16886879 | 0.83 | CA1 (0.71) | CA1CA2PDPK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL18422806 | 0.83 | CA1 (0.71) | CA1CA2PDPK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL6337843 | 0.83 | CA1 (0.71) | CA1CA2PDPK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL18422395 | 0.83 | CA1 (0.71) | CA1CA2PDPK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL30024474 | 0.83 | CA1 (0.71) | CA1CA2PDPK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL8404960 | 0.80 | ALDH1A1 (0.69) | CA1CA2PDPK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL6937422 | 0.80 | CA1 (0.67) | CA1CA2PDPK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL2464696 | 0.80 | CA1 (0.67) | CA1CA2PDPK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL6932458 | 0.80 | CA1 (0.67) | CA1CA2PDPK1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3769759-B1 | COMBINATION OF AN INDANESULFAMIDE DERIVATIVE WITH PERAMPANEL FOR USE IN THE TREATMENT OF EPILEPSY | EISAI R&D MAN CO LTD (JP) | 2023-11-15 | — | — | EP | disclosed |
| US-11660275-B2 | Epilepsy treatment agent | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-05-30 | — | — | US | disclosed |
| EP-3769759-A1 | EPILEPSY TREATMENT AGENT | Eisai R&D Management Co., Ltd. (JP) | 2021-01-27 | — | — | EP | disclosed |
| US-20210000771-A1 | EPILEPSY TREATMENT AGENT | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-01-07 | — | — | US | disclosed |
| WO-2019181854-A1 | EPILEPSY TREATMENT AGENT | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 2019-09-26 | — | — | WO | disclosed |
| EP-3085369-B1 | THERAPEUTIC AND/OR PREVENTIVE AGENT COMPRISING 1-INDANSULFAMIDE DERIVATIVE FOR PAIN | EISAI R&D MAN CO LTD (JP) | 2018-04-04 | — | — | EP | disclosed |
| EP-2865663-B1 | NOVEL INDANESULFAMIDE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2017-04-05 | — | — | EP | disclosed |
| EP-2865663-B1 | NOVEL INDANESULFAMIDE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2017-04-05 | — | — | EP | disclosed |
| US-9610262-B2 | Therapeutic and/or preventive agent comprising 1-indansulfamide derivative for pain | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-04-04 | — | — | US | disclosed |
| US-9610262-B2 | Therapeutic and/or preventive agent comprising 1-indansulfamide derivative for pain | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-04-04 | — | — | US | disclosed |
| EP-2865663-A1 | NOVEL INDANESULFAMIDE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2015-04-29 | — | — | EP | disclosed |
| EP-2865663-A1 | NOVEL INDANESULFAMIDE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2015-04-29 | — | — | EP | disclosed |
| US-9018260-B2 | Indanesulfamide derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-28 | — | — | US | disclosed |
| US-9018260-B2 | Indanesulfamide derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-28 | — | — | US | disclosed |
| US-9018260-B2 | Indanesulfamide derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-28 | — | — | US | disclosed |
| US-20140371319-A1 | NOVEL INDANESULFAMlDE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-12-18 | — | — | US | disclosed |
| US-20140371319-A1 | NOVEL INDANESULFAMlDE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-12-18 | — | — | US | disclosed |
| US-20140371319-A1 | NOVEL INDANESULFAMlDE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-12-18 | — | — | US | disclosed |
| EP-1884515-A1 | Substituted indanyl sulfonamide compounds, their preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2008-02-06 | — | — | EP | disclosed |
| US-4044151-A | Sulfamidophenethanolamine therapeutic process | MEAD JOHNSON & COMPANY (US) | 1977-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11660275-B2 | Epilepsy treatment agent | GRIK4, GRIK1, GRIK2 | CA1 303/4885CA2 557/4885PDPK1 1949/4885 |
| US-20140371319-A1 | NOVEL INDANESULFAMlDE DERIVATIVES | SCN1A, SCN7A, SCN2A | CA1 219/4885CA2 315/4885PDPK1 3381/4885 |
| US-20210000771-A1 | EPILEPSY TREATMENT AGENT | GRIK4, GRIK1, GRIK2 | CA1 303/4885CA2 557/4885PDPK1 1949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.